Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Muser

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
The Prostate|April 30, 2024
Differences in real-world outcomes by risk classification for localized prostate cancer patients after radiation therapyLawrence Karsh, Shawn Du, Jinghua He, et al.
Journal of Comparative Effectiveness Research|May 4, 2018
Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare populationKruti Joshi, Erik Muser, Yihua Xu, et al.
Crohn'S & Colitis 360|February 13, 2023
Work-Related Productivity Loss and Associated Indirect Costs in Patients With Crohn's Disease or Ulcerative Colitis in the United StatesZhijie Ding, Erik Muser, James Izanec, et al.
BMC Psychiatry|June 4, 2017
Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophreniaDominic Pilon, Erik Muser, Patrick Lefebvre, et al.
The Journal of Dermatological Treatment|November 13, 2019
Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured populationBingcao Wu, Erik Muser, Amanda Teeple, et al.
Crohn'S & Colitis 360|February 13, 2023
Persistence, Dosing, and Other Treatment Patterns Among Crohn's Disease Patients Initiating Biologics in United StatesAmanda Teeple, Janvi Sah, Rajesh Mallampati, et al.
Journal of Medical Economics|March 5, 2011
Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychoticsKathleen Lang, Jonathan Korn, Erik Muser, et al.
Drugs - Real World Outcomes|December 23, 2015
Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical AntipsychoticsJacqueline A Pesa, Erik Muser, Leslie B Montejano, et al.
Journal of Medical Economics|December 8, 2018
The economic burden of psoriasis with high comorbidity among privately insured patients in the United StatesDominic Pilon, Amanda Teeple, Masha Zhdanava, et al.
The Journal of Dermatological Treatment|July 16, 2019
Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumabKristian Reich, Peter Foley, Chenglong Han, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
The Prostate|April 30, 2024
Differences in real-world outcomes by risk classification for localized prostate cancer patients after radiation therapyLawrence Karsh, Shawn Du, Jinghua He, et al.
Journal of Comparative Effectiveness Research|May 4, 2018
Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare populationKruti Joshi, Erik Muser, Yihua Xu, et al.
Crohn'S & Colitis 360|February 13, 2023
Work-Related Productivity Loss and Associated Indirect Costs in Patients With Crohn's Disease or Ulcerative Colitis in the United StatesZhijie Ding, Erik Muser, James Izanec, et al.
BMC Psychiatry|June 4, 2017
Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophreniaDominic Pilon, Erik Muser, Patrick Lefebvre, et al.
The Journal of Dermatological Treatment|November 13, 2019
Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured populationBingcao Wu, Erik Muser, Amanda Teeple, et al.
Crohn'S & Colitis 360|February 13, 2023
Persistence, Dosing, and Other Treatment Patterns Among Crohn's Disease Patients Initiating Biologics in United StatesAmanda Teeple, Janvi Sah, Rajesh Mallampati, et al.
Journal of Medical Economics|March 5, 2011
Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychoticsKathleen Lang, Jonathan Korn, Erik Muser, et al.
Drugs - Real World Outcomes|December 23, 2015
Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical AntipsychoticsJacqueline A Pesa, Erik Muser, Leslie B Montejano, et al.
Journal of Medical Economics|December 8, 2018
The economic burden of psoriasis with high comorbidity among privately insured patients in the United StatesDominic Pilon, Amanda Teeple, Masha Zhdanava, et al.
The Journal of Dermatological Treatment|July 16, 2019
Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumabKristian Reich, Peter Foley, Chenglong Han, et al.
Pageof 5